+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-11-06Number of Pages: 78

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Global Hypertrophic Cardiomyopathy Therapeutics Market – Key Trends 

With heart diseases emerging as one of the most common causes of mortality among men and women worldwide, Transparency Market Research (TMR) expects the demand for hypertrophic cardiomyopathy (HCM) therapeutics to surge considerably. Furthermore, the market is expected to gain significant impetus from successful government interventions aimed at spreading awareness about hypertrophic cardiomyopathy.

TMR projects the global HCM therapeutics market to expand at a moderate 1.4% CAGR between 2015 and 2023. Despite witnessing positive opportunities, the rising demand for advanced medical devices could threaten the market’s growth to an extent. Nevertheless, since the majority of HCM drugs are yet to get approved, the hypertrophic cardiomyopathy therapeutics market is likely to gain momentum post their approval in the near future.

According to TMR, the global hypertrophic cardiomyopathy therapeutics market is expected to reach US$1.37 bn in 2023, from US$1.2 bn in 2015. The leading players in the market are likely to capitalize on the untapped opportunities in the healthcare sector of emerging economies to expand their footprint.

Rising Use of Calcium Channel Blockers Being Witnessed in Obstructive HCM Treatment

Antiarrhythmic drugs, anti-coagulating agents, calcium channel blockers, and beta blockers are the most recommended therapies for the treatment of HCM. By drug class, the calcium channel blockers segment held the leading share of 37.4% in the HCM therapeutics market in 2014. This drug provides an effective alternative to beta-blocker therapy particularly used in obstructive HCM treatment. As per TMR, the calcium channel blockers segment is expected to rise at a CAGR of 1.8% from 2015 to 2023.

The beta adrenergic blocking agents emerged as the second-largest segment in 2014. The most common beta adrenergic blocking agents preferred in HCM treatment include atenolol, metoprolol, propranolol, and sotalol. 

Due to the increasing sedentary lifestyle and unhealthy choices, experts project the incidence of heart disease to rise considerably in the forthcoming years. This will subsequently boost demand for HCM therapeutics through the forecast period.

Rising Prevalence of Obesity to Fuel Demand for HCM Therapeutics in North America

North America, Europe, Asia Pacific, and Rest of the World constitute the key markets by geography for HCM therapeutics. Among these regions, with a share of 31.1%, North America emerged as the leading contributor to the market in 2014, followed by Europe. Both these regions boast a sophisticated healthcare infrastructure, which augurs well for the HCM therapeutics market.

The increasing prevalence of obesity among the younger population in North America and their preference towards a sedentary lifestyle, are primary factors augmenting demand for HCM therapeutics from the region. The rising cases of cardiac arrests reported every year in North America will seal the region’s dominance in the market through the forecast period. In North America, the U.S. reports the highest demand for HCM therapeutics.

However, according to TMR, the market is expected to witness stronger growth across the emerging economies of Asia Pacific and Rest of the World. Asia Pacific is expected to report the fastest CAGR during the course of the forecast period. The development of modern healthcare facilities in the region, rising healthcare expenditure, and the increasing awareness about HCM, are primary factors fuelling demand for HCM therapeutics from Asia Pacific.

Some of the leading companies in the global hypertrophic cardiomyopathy therapeutics market are Sanofi S.A., Merck & Co., Pfizer, Inc., Mylan N. V. Teva Pharmaceuticals Limited, Novartis AG, and Others.

 

1. Preface
     1.1. Report Description
     1.2. Market Segmentation
     1.3. Research Methodology

2. Executive Summary
     2.1. Hypertrophic Cardiomyopathy Therapeutics: Market Snapshot
     2.2. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Geography, 2014 & 2023 (Value %)
     2.3. Global Hypertrophic Cardiomyopathy Therapeutics Market, by Drug Class, 2014 (US$ Mn)

3. Hypertrophic Cardiomyopathy Therapeutics Market - Industry Analysis
     3.1. Introduction
     3.2. Epidemiology and Prognosis: Hypertrophic Cardiomyopathy
     3.3. Market Dynamics
            3.3.1. Drivers
                     3.3.1.1. Driver 1: Increasing prevalence of chronic cardiovascular diseases to increase demand for effective treatments
                     3.3.1.2. Driver 2: High awareness associated with HCM in developed countries
            3.3.2. Restraints
                     3.3.2.1. Restraint 1: Rising technological upgradation in devices such as defibrillators and pacemakers
            3.3.3. Opportunities
                     3.3.3.1. Opportunity 1: Targeted therapy for hypertrophic cardiomyopathy
     3.4. Market Attractiveness Analysis - Hypertrophic Cardiomyopathy Therapeutics Market, by Geography, 2014
     3.5. Competitive Landscape 
     3.6. Global Hypertrophic Cardiomyopathy Therapeutics Market Share, by Key Players, 2014 (%)

4. Market Segmentation – By Drug
     4.1. Introduction
            4.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
     4.2. Global Beta Adrenergic Blocking Agents Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.3. Global Calcium Channel Blockers Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.4. Global Antiarrhythmic Agents Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.5. Global Anticoagulants  Market Revenue, 2013–2023 (US$ Mn) and Analysis

5. Pipeline Analysis
     5.1. Overview
     5.2. Phase II and Phase I Clinical Trials

6. Market Segmentation – By Geography
     6.1. Introduction
            6.1.1. Global Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Region, 2013–2023 (US$ Mn)
     6.2. North America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
            6.2.1. U.S. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.2.2. Canada Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
     6.3. Europe Hypertrophic Cardiomyopathy Therapeutics Market – Revenue, by Country, 2013–2023 (US$ Mn)
            6.3.1. U.K. Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.3.2. Germany Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.3.3. Rest of Europe Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
     6.4. Asia Pacific Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
            6.4.1. India Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.4.2. Japan Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.4.3. Rest of APAC Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
     6.5. Rest of the World Hypertrophic Cardiomyopathy Therapeutics Market Revenue, by Country, 2013–2023 (US$ Mn)
            6.5.1. Latin America Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.5.2. Middle East Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)
            6.5.3. Africa Hypertrophic Cardiomyopathy Therapeutics Market Revenue, 2013–2023, (US$ Mn)

7. Recommendations
     7.1. Recommendation 1: Companion diagnostics would help to increase the diagnostic rate and ultimately the drugs market 

8. Company Profiles
     8.1. Astra Zeneca plc
     8.2. Concordia Healthcare Corp.
     8.3. Gilead Sciences, Inc.
     8.4. Merck & Co., Inc.
     8.5. Mylan N.V.
     8.6. Novartis AG
     8.7. Pfizer, Inc. 
     8.8. Sanofi S.A.
     8.9. Teva Pharmaceutical Industries Ltd

This report on the hypertrophic cardiomyopathy therapeutics market studies the current and future prospects of the global market. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and cause the walls of the ventricles (usually the left ventricle) to thicken. However, the thickening may block blood flow out of the ventricle and the condition is called obstructive hypertrophic cardiomyopathy. Modern healthcare infrastructure, increasing sedentary lifestyle in young population and rising obese population are expected to propel the global hypertrophic cardiomyopathy therapeutics market.

The hypertrophic cardiomyopathy therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global hypertrophic cardiomyopathy therapeutics market with respect to the segments based on the type of drug class, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global hypertrophic cardiomyopathy therapeutics market.  

Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been segmented into four major categories: Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Antiarrhythmic Agents, and Anticoagulants. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the global hypertrophic cardiomyopathy therapeutics market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, India, Rest of Asia Pacific), and Rest of the World (Latin America, Middle East, Africa). The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global hypertrophic cardiomyopathy therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG

The global hypertrophic cardiomyopathy therapeutics market is segmented as follows:

Global Hypertrophic Cardiomyopathy Therapeutics, by Drug Class

  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blockers
  • Antiarrhythmic Agents
  • Anticoagulants  

Global Hypertrophic Cardiomyopathy Therapeutics, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa